CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
DCP-003 NCI Oncologists’ Knowledge, Attitudes, and Practices for Comorbidity Management Cancer Prevention and Control CIRB
E1105 ECOG A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer Adult CIRB - Late Phase Emphasis
E1208 ECOG A Phase III Randomized; Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion Adult CIRB - Late Phase Emphasis
E1301 ECOG A Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With States III/IV Head and Neck Squamous Cell Carcinoma Adult CIRB - Late Phase Emphasis
E1302 ECOG Phase III Randomized; Placebo-Controlled Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa; Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer Adult CIRB - Late Phase Emphasis
E1305 ECOG A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer Adult CIRB - Late Phase Emphasis
E1505 ECOG A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>= 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC) Adult CIRB - Late Phase Emphasis
E1609 ECOG A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma<br> Adult CIRB - Late Phase Emphasis
E1899 ECOG Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) versus Docetaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients with a Rising PSA after Hormonal Therapy for Prostate Cancer Adult CIRB - Late Phase Emphasis
E1900 ECOG A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-<br>Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation Adult CIRB - Late Phase Emphasis